Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

990
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
990
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.4K
Management of Insomnia01:19

Management of Insomnia

788
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
788
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

7.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes.

ACS chemical neuroscience·2022
Same author

Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine.

Journal of medicinal chemistry·2020
Same author

Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators.

Advances in pharmacology (San Diego, Calif.)·2020
Same author

Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.

Journal of medicinal chemistry·2019
Same author

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.

Journal of medicinal chemistry·2019
Same author

Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design.

Bioorganic & medicinal chemistry letters·2019
Same journal

Patent highlights December 2023-January 2024.

Pharmaceutical patent analyst·2025
Same journal

Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight.

Pharmaceutical patent analyst·2025
Same journal

Patent highlights April-May 2024.

Pharmaceutical patent analyst·2025
Same journal

Patent highlights June - July 2024.

Pharmaceutical patent analyst·2025
Same journal

Patent highlights February-March 2024.

Pharmaceutical patent analyst·2025
Same journal

Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment.

Pharmaceutical patent analyst·2025
See all related articles

Related Experiment Video

Updated: May 5, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

24.1K

Orexin receptor antagonists.

John A Christopher1

  • 1Heptares Therapeutics Limited, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK. john.christopher@heptares.com.

Pharmaceutical Patent Analyst
|November 19, 2013
PubMed
Summary
This summary is machine-generated.

Small molecules targeting orexin receptors show promise for treating insomnia. This review covers patent activity for dual orexin receptor antagonists from 2009-2011.

More Related Videos

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.3K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.0K

Related Experiment Videos

Last Updated: May 5, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

24.1K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.3K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.0K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Intellectual Property

Background:

  • Orexin neuropeptides regulate sleep-wake cycles by binding to orexin-1 and orexin-2 receptors.
  • Small-molecule antagonists of these receptors are being developed for therapeutic applications, particularly for insomnia.
  • Dual orexin receptor antagonists represent an advanced class of these therapeutics.

Purpose of the Study:

  • To provide a comprehensive review of patent activity related to small-molecule orexin antagonists.
  • To analyze trends in orexin antagonist patent filings between 2009 and 2011.

Main Methods:

  • Literature search of patent databases.
  • Analysis of patent filings for small-molecule orexin antagonists.
  • Categorization of patents based on therapeutic targets and chemical structures.

Main Results:

  • Significant patent activity was observed in the field of small-molecule orexin antagonists during the 2009-2011 period.
  • Patents covered various chemical scaffolds and therapeutic applications, with a focus on dual orexin receptor antagonists.
  • Key pharmaceutical companies and research institutions were identified as major patent applicants.

Conclusions:

  • The period 2009-2011 was characterized by substantial innovation and patent filings in the development of small-molecule orexin antagonists.
  • This patent landscape highlights the growing therapeutic interest and investment in orexin receptor antagonism, especially for insomnia treatment.